S100A4 neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.
Xiao ŠvecHana ŠtorkánováThuong Trinh-MinhManh Cuong TranLenka ŠtorkánováHana HulejováSabína OreskáBarbora HeřmánkováRadim BečvářKarel PavelkaJiří VencovskýJörg KlingelhöferRizwan I HussainJonas HallénLadislav ŠenoltJörg H W DistlerMichal TomcikPublished in: Rheumatology (Oxford, England) (2023)
Targeting S100A4 by the 6B12 mAb demonstrated potent antifibrotic and anti-inflammatory effects on bleomycin-induced dermal fibrosis and provided further evidence for the vital role of S100A4 in the pathophysiology of SSc.